Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Six months ended June 30, 2006
Business Overview: Neurocrine discovers, develops, and intends to commercialize drugs for neurological and endocrine-related diseases. The company's lead clinical program is indiplon, a drug candidate for insomnia. As of June 30, 2006, the company had eight programs in various stages of research and development, including six in clinical development.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2006 | Six Months Ended June 30, 2005 |
|---|---|---|
| Total Revenues | $28,720 | $45,033 |
| Net Loss | $(53,350) | $(24,434) |
| Net Loss Per Share (Basic & Diluted) | $(1.42) | $(0.67) |
| Operating Expenses | $85,578 | $70,632 |
| Cash and Cash Equivalents (End of Period) | $86,168 | $48,499 |
| Short-term Investments | $148,151 | $223,120 |
| Total Current Assets | $240,627 | $279,310 |
| Total Liabilities | $80,771 | $93,019 |
| Long-term Debt | $51,205 | $53,590 |
| Net Cash Used in Operating Activities | $(48,793) | $(53,487) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 36% ($16.3 million) compared to the prior year period. This was primarily due to the absence of a $20.0 million milestone payment from Pfizer recognized in 2005 related to the FDA acceptance of the indiplon NDA.
- Increased Net Loss: Net loss increased by approximately 118% ($28.9 million). The increase is attributed to the loss of the $20.0 million Pfizer milestone and the adoption of SFAS 123R (Share-Based Payment), which added $9.5 million in non-cash compensation expense.
- Expense Increases: Sales, general, and administrative (SG&A) expenses rose significantly ($16.4 million increase) due to sales force activities and SFAS 123R adoption. Research and development (R&D) expenses decreased slightly ($1.4 million) due to lower external development costs for indiplon, partially offset by increased personnel costs.
- Liquidity: Cash and cash equivalents increased by $36.2 million during the period, driven by net cash provided by investing activities (sales/maturities of short-term investments) and financing activities (stock option exercises), offsetting the net cash used in operations.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Indiplon FDA Status: On May 15, 2006, the FDA issued complete response letters. The 5 mg and 10 mg capsules were deemed "approvable" pending data reanalysis, while the 15 mg tablets were deemed "not approvable" due to insufficient sleep maintenance data. The company is scheduled to meet with the FDA in August 2006 to discuss next steps.
- Pfizer Collaboration Termination: On June 22, 2006, Neurocrine and Pfizer agreed to terminate their collaboration effective December 19, 2006. Neurocrine will reacquire all worldwide rights to indiplon. Pfizer will no longer reimburse the sales force after June 30, 2006.
- Workforce Reduction: The company terminated its entire sales force in July 2006 and reduced R&D and administrative staff by approximately 100 employees in August 2006. Estimated expenses for these reductions are approximately $9.5 million in the third quarter of 2006.
- 2006 Guidance: Management expects a net loss of approximately $135.0 million for fiscal year 2006, including the $9.5 million reduction in force expense and non-cash SFAS 123R expenses.
Risks and Contingencies
- Regulatory Uncertainty: Approval of indiplon is not guaranteed. Additional clinical trials or data analysis may be required, incurring significant costs and delays.
- Commercialization Risk: Following the Pfizer termination, Neurocrine must either find a new partner or build its own commercial infrastructure to market indiplon, which requires substantial resources.
- Asset Impairment: The company holds a $94.0 million prepaid royalty asset related to indiplon. While no impairment was recognized as of June 30, 2006, future FDA actions or commercialization failures could trigger a material impairment charge.
- Liquidity: The company expects to incur operating losses for the foreseeable future and may require additional funding through strategic alliances or equity/debt financing.
Key Facts for Investor Verification
- FDA Action Letters: Verify the specific data reanalysis requirements for the "approvable" indiplon capsules and the clinical data gaps for the "not approvable" tablets.
- Post-Termination Strategy: Confirm the timeline and cost estimates for Neurocrine to either secure a new commercial partner or build an independent sales force for indiplon.
- Impairment Analysis: Monitor the quarterly assessment of the $94.0 million prepaid royalty asset for potential impairment charges given the regulatory hurdles.
- Cash Burn Rate: Track the impact of the $9.5 million workforce reduction expense and the loss of Pfizer reimbursement on the company's cash runway.
- Stock-Based Compensation: Note the significant impact of SFAS 123R adoption on reported net loss ($9.5 million for the six months ended June 30, 2006).